Payment overview · 2025
General Payments
$6,531.96
76 reported records · 11 companies
Healthcare provider profile · identity verified
Chandra S Bomma, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · ORLANDO, FL · NPI 1962517433
Verified facts
What the public records show
CMS Open Payments records show Chandra S Bomma, MD received $6,531.96 in general payments during 2025 across 76 reported records.
Medtronic, Inc. accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 517 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$2,045.11 | 31.3% | 22 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,768.40 | 27.1% | 11 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $1,516.86 | 23.2% | 12 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $670.40 | 10.3% | 10 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $208.31 | 3.2% | 15 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $134.78 | 2.1% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $58.94 | 0.9% | 1 | 2025 |
| Stereotaxis Inc | Unresolved — no canonical attribution shown | $55.51 | 0.8% | 1 | 2025 |
| Vektor Medical Inc. | Unresolved — no canonical attribution shown | $38.40 | 0.6% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $18.86 | 0.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.39 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,043.65 | 68 |
| Travel and Lodging | $1,432.80 | 6 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000.00 | 1 |
| Entertainment | $55.51 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $1,500.38 | 11 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $1,106.50 | 2 | 2025 |
Source payment records
|
|||||
| ENSITE PRECISION Normalized: ensite precision |
Device | Abbott Laboratories | $387.81 | 4 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $364.93 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $305.03 | 3 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $191.02 | 6 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $174.35 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $157.07 | 10 | 2025 |
Source payment records
|
|||||
| TACTICATH ABLATION CATHETER, SENSOR ENABLED Normalized: tacticath ablation catheter sensor enabled |
Device | Abbott Laboratories | $134.89 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $131.90 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $114.73 | 2 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $94.69 | 1 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $58.94 | 1 | 2025 |
Source payment records
|
|||||
| Genesis Normalized: genesis |
Device | Stereotaxis Inc | $55.51 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $51.24 | 5 | 2025 |
Source payment records
|
|||||
| vMap Normalized: vmap |
Device | Vektor Medical Inc. | $38.40 | 1 | 2025 |
Source payment records
|
|||||
| ENSITE Normalized: ensite |
Device | Abbott Laboratories | $27.40 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $4.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 517 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
517 | 148 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 517 | 148 |
| Metoprolol Tartrate | Metoprolol Tartrate | 220 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 64 |
| Dofetilide | Dofetilide | 176 | 43 |
| Flecainide Acetate | Flecainide Acetate | 159 | 55 |
| Sotalol | Sotalol Hcl | 131 | 44 |
| Amiodarone Hcl | Amiodarone Hcl | 110 | 40 |
| Enoxaparin Sodium | Enoxaparin Sodium | 106 | 68 |
| Multaq | Dronedarone Hcl | 90 | 25 |
| Xarelto | Rivaroxaban | 86 | 20 |
| Carvedilol | Carvedilol | 74 | 28 |
| Losartan Potassium | Losartan Potassium | 71 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 63 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 55 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 16 |
| Lisinopril | Lisinopril | 43 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 36 | 13 |
| Furosemide | Furosemide | 35 | 14 |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 26 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,531.96 · 76 records | Medtronic, Inc. | AFFERA MAPPING SYSTEM, AMPLATZER AMULET, AMVIA EDGE, AVEIR, CARTO 3, ELIQUIS, ENSITE, ENSITE PRECISION, FARAPULSE, FFRct, General - Tachy, General - Therapies, Genesis, Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor, LINQ II, MERLIN@HOME, MICRA, NUVISION ICE CATHETER, SYMPLICITY G3, TACTICATH ABLATION CATHETER, SENSOR ENABLED, vMap | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error